Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload
Piga, A, Galanello, R, Forni, GL, Cappellini, MD, Origa, R, Zappu, A, Donato, G, Bordone, E, Lavagetto, A, Zanaboni, L, Sechaud, R, Hewson, N, Ford, JM, Opitz, H, Alberti, D
Published in Haematologica (Roma) (01.07.2006)
Get full text
Published in Haematologica (Roma) (01.07.2006)
Journal Article
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major
Galanello, R, Piga, A, Forni, GL, Bertrand, Y, Foschini, ML, Bordone, E, Leoni, G, Lavagetto, A, Zappu, A, Longo, F, Maseruka, H, Hewson, N, Sechaud, R, Belleli, R, Alberti, D
Published in Haematologica (Roma) (01.10.2006)
Get full text
Published in Haematologica (Roma) (01.10.2006)
Journal Article
Once-Daily Treatment with the Oral Iron Chelator ICL670 (Exjade®): Results of a Phase II Study in Pediatric Patients with β-Thalassemia Major
Piga, Antonio, Galanello, Renzo, Foschini, Maria Loreta, Zappu, Antonella, Bordone, Elena, Longo, Filomena, Forni, Gian-Luca, Lavagetto, Antonella, Bertrand, Yves, Maseruka, Henry, Latham, Nicola, Alberti, Daniele
Published in Blood (16.11.2004)
Published in Blood (16.11.2004)
Get full text
Journal Article